{"id":2435,"date":"2016-04-17T07:17:07","date_gmt":"2016-04-17T11:17:07","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=2435"},"modified":"2016-04-21T21:39:00","modified_gmt":"2016-04-22T01:39:00","slug":"the-brave-new-world-of-infectious-diseases","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2016\/04\/17\/2435\/the-brave-new-world-of-infectious-diseases\/","title":{"rendered":"The Brave New World of Infectious Diseases"},"content":{"rendered":"

\"ECCMID<\/a><\/p>\n

Coming back from ECCMID, one\u00a0gets the impression that we are moving towards an era in which\u00a0we can diagnose everything but treat nothing. A late breaker session on colistin resistance provided much detail data on the situation in the EU.<\/p>\n

As we know, colistin resistance conferred by the mcr-1 gene has been found on all continents, on plasmids and on chromosomes, in humans, in livestock and in the environment. It has been around for a few years already, but we just did not know it.<\/p>\n

In western European countries, the prevalence of colistin resistance in livestock (mainly pigs) was 3.5% in E. coli and 9.9% for Salmonella based on 10-yr surveillance data (2004-2014) presented at the conference. Over 19% of the colistin-resistant E. coli carried the mcr-1 gene. There was no evidence of increasing resistance over the years. Several standard antibiotics are still quite effective.\u00a0The message from the veterinary perspective: not to\u00a0worry.<\/p>\n

The Netherlands, always on the forefront of antibiotic stewardship in Europe, seems to have things under reasonable control. The Dutch have been monitoring the situation and significantly reduced the use of polymyxins in animal feed. While they may be an island of tranquility,other countries have much higher mcr-1 resistance rates, as shown below in Table 1.<\/p>\n

\"mcr-1<\/a>
Table 1: mrc-1 resistance (presentation by Liz Terveer, Leiden, ECCMID 2016)<\/figcaption><\/figure>\n

In Italy, approximately 1\/2 of K. pneumoniae were carbapenemase producers and approx. 1\/3 of K. pneumoniae were colistin-resistant in 2015. \u00a0Both rates were considerably lower just 1 year earlier, in 2014.<\/p>\n

Further data were presented documenting the progression of colistin resistance in various enteric pathogens isolated from human sources.<\/p>\n

\"Camilla<\/a>
Camilla Rodrigues, MD – Convenor<\/figcaption><\/figure>\n

Repeatedly the recommendation was made by speakers that more data was needed. Good point, thanks for stating the obvious. Such tepid advice has become the norm; however, it has hardly been a recipe to deal with the core issue. It seems that most ID folks have an excellent analytical mind, but only few put the data pieces together in a synthetic integrative manner.<\/p>\n

So, we were actually surprised to hear Dr. Camilla Rodrigues (Mumbai, India \u2013 faculty\/convenor) state in her session summary that it was time to stop the veterinary use of colistin. Thank you, Dr. Rodrigues, you said what others were not courageous enough to say. You provided the over-arching holistic perspective and showed civil courage so rarely seen\u00a0at these sessions. You saved the day.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Coming back from ECCMID, one\u00a0gets the impression that we are moving towards an era in which\u00a0we can diagnose everything but treat nothing. A late breaker session on colistin resistance provided much detail data on the situation in the EU. As we know, colistin resistance conferred by the mcr-1 gene has Continue reading The Brave New World of Infectious Diseases<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":2439,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[3,18],"tags":[1271,403,334,177,1591,298,1589,1590,1583,296,1592,1049,1460],"class_list":["post-2435","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-the_news","category-the_viewpoint","tag-allphase-pharma-consulting","tag-antibiotic-blog","tag-antibiotic-stewardship","tag-colistin","tag-colistin-resistance","tag-e-coli","tag-eccmid","tag-eccmid-2016","tag-harald-reinhart","tag-klebsiella","tag-mcr-1","tag-salmonella","tag-veterinary-antibiotics"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/04\/ECCMID-slider.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-Dh","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":1629,"url":"https:\/\/allphasepharma.com\/dir\/2015\/06\/29\/1629\/nitrofurantoin-an-old-drug-resurrected-needs-prospective-scrutiny\/","url_meta":{"origin":2435,"position":0},"title":"Nitrofurantoin \u2013 An Old Drug Resurrected Needs Prospective Scrutiny","author":"Harald","date":"June 29, 2015","format":false,"excerpt":"When older drugs get reintroduced into clinical practice because pathogens have developed resistance to newer agents, it comes at the price of uncertainty. Often, older drugs were approved based on rather limited\u00a0data, often considered incomplete by today\u2019s standards.\u00a0 Take colistin as an example: approved in the early 60ies, we still\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"UTI - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/06\/UTI-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/06\/UTI-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/06\/UTI-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":3071,"url":"https:\/\/allphasepharma.com\/dir\/2017\/01\/19\/3071\/cdc-report-pan-resistant-ndm-klebsiella-nevada-sad-tale\/","url_meta":{"origin":2435,"position":1},"title":"CDC Report on Pan-Resistant NDM Klebsiella in Nevada\u2013 A Sad Tale","author":"Harald","date":"January 19, 2017","format":false,"excerpt":"During the past few weeks the case of a patient with MDR Klebsiella infection has made the news. We are told that this particular pathogen is \u201cresistant to 26 antibiotics\u201d. We were informed that the patient had multiple prior hospitalizations in India, supposedly the origin of the uncontrolled untreatable infection.\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/CDC-KP-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/CDC-KP-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/CDC-KP-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1981,"url":"https:\/\/allphasepharma.com\/dir\/2015\/10\/05\/1981\/polyphor-pol-7080-and-the-journey-to-the-land-of-pyocyanea-part-1\/","url_meta":{"origin":2435,"position":2},"title":"Polyphor POL7080 And The Journey to The Land of Pyocyanea\u00a0 (Part 1)","author":"Harald","date":"October 5, 2015","format":false,"excerpt":"When Roche inlicensed Polyphor\u2019s anti-pseudomonas drug POL7080 in November 2013, it marked a turning point. It seemed that Big Pharma that had all but abandoned the field in the last decade and was getting engaged in anti-infectives again. When a company with as\u00a0much experience in antibiotic drug development as Roche\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"bridge Pyocyanea copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1401,"url":"https:\/\/allphasepharma.com\/dir\/2015\/04\/30\/1401\/a-renaissance-for-old-drugs-fosfomycin-and-colistin\/","url_meta":{"origin":2435,"position":3},"title":"A Renaissance for Old Drugs: Fosfomycin and Colistin","author":"Harald","date":"April 30, 2015","format":false,"excerpt":"Fosfomycin Who would have thought that a drug that has been around since 1969 [2] could become eligible for QIDP status in 2015? Well, Zavante Therapeutics recently garnered the coveted QIDP designation for fosfomycin IV. This formulation has been available in Europe for a quite some\u00a0time but not in the\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":972,"url":"https:\/\/allphasepharma.com\/dir\/2014\/09\/29\/972\/perusing-the-literature\/","url_meta":{"origin":2435,"position":4},"title":"Perusing the Literature","author":"Harald","date":"September 29, 2014","format":false,"excerpt":"Inhibitor\u00a0of the\u00a0NDM\u00a0Enzyme Aspergillomarasmine (AMA) was identified as an inhibitor of the New Delhi metallo-betalactamase (NDM) enzyme. This substance, when combined with meropenem, restored antibiotic activity against an NDM lab strain.\u00a0 \u00a0AMA is a substance which was already tested in the past in humans.\u00a0 Concerns about interference with human metalloenzymes proved\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/09\/NewLit-slider-copy.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/09\/NewLit-slider-copy.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/09\/NewLit-slider-copy.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":2186,"url":"https:\/\/allphasepharma.com\/dir\/2015\/12\/19\/2186\/aztreonam-plus-avibactam-a-new-bright-star-in-the-night-sky\/","url_meta":{"origin":2435,"position":5},"title":"Aztreonam PLUS Avibactam \u2013 A New Bright Star in the Night Sky","author":"Harald","date":"December 19, 2015","format":false,"excerpt":"Looking at the molecular structure of ceftazidime (CTAZ) and aztreonam (ATM), the differences are clear, and so are the similarities: ATM does not have the cephem ring structure of CTAZ, only the 4-member beta-lactam ring.\u00a0 However, the side chains are identical in both CTAZ and ATM which explains the overlapping\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"Avibactam - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/Avibactam-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/Avibactam-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/Avibactam-slider.jpg?resize=525%2C300 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/Avibactam-slider.jpg?resize=700%2C400 2x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=2435"}],"version-history":[{"count":5,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2435\/revisions"}],"predecessor-version":[{"id":2444,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2435\/revisions\/2444"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/2439"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=2435"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=2435"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=2435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}